Drug Overview
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis, and have demonstrated that inhibition of both PDGF and VEGF results in reduced tumor vascularization and greater growth inhibition.
Analyst Outlook
Votrient (pazopanib; Novartis) is expected to struggle to retain market share as newer, more efficacious combinations enter the market. Votrient is not currently in development in combination with an immuno-oncology therapy, though Votrient + Keytruda (pembrolizumab; Merck & Co) was investigated in a Phase I/II clinical trial for the first-line treatment of advanced renal cell carcinoma (RCC) (ClinicalTrials.gov identifier: NCT02014636). In this trial, the combination showed significant hepatotoxicity, and was deemed not to be suitable to advance to Phase III trials. Further opportunity for Votrient in RCC may come following the result of an ongoing clinical trial investigating the efficacy and safety of Votrient in the second-line setting following treatment with a checkpoint inhibitor (ClinicalTrials.gov identifier: NCT03200717). As checkpoint inhibitors become increasingly important in the first-line treatment of advanced RCC, Votrient may be able to satisfy an unmet need and increase its market share
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis, and have demonstrated that inhibition of both PDGF and VEGF results in reduced tumor vascularization and greater growth inhibition.
Analyst Outlook
Votrient (pazopanib; Novartis) is expected to struggle to retain market share as newer, more efficacious combinations enter the market. Votrient is not currently in development in combination with an immuno-oncology therapy, though Votrient + Keytruda (pembrolizumab; Merck & Co) was investigated in a Phase I/II clinical trial for the first-line treatment of advanced renal cell carcinoma (RCC) (ClinicalTrials.gov identifier: NCT02014636). In this trial, the combination showed significant hepatotoxicity, and was deemed not to be suitable to advance to Phase III trials. Further opportunity for Votrient in RCC may come following the result of an ongoing clinical trial investigating the efficacy and safety of Votrient in the second-line setting following treatment with a checkpoint inhibitor (ClinicalTrials.gov identifier: NCT03200717). As checkpoint inhibitors become increasingly important in the first-line treatment of advanced RCC, Votrient may be able to satisfy an unmet need and increase its market share
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
